Skip to main content

Nucleic Acid Standards for Biosecurity Act (H.R. 3029)

Referred to Committee

To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.

Introduced 4/28/2025•119th Congress•House

Latest Action

Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.

7/21/2026 • Senate

Summary

Nucleic Acid Standards for Biosecurity Act

This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.

Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).

The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)

In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress.

NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.

Introduced in House • 4/28/2025

Enter your district to see how this bill affects your community
-

Topics & Subjects

Biological and life sciencesCell biology and embryologyResearch and development

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (4)

Party Breakdown

3
Democrats
1
Republicans
0
Independents

Sponsor

R[
Rep. Salinas, Andrea [D-OR-6]

Democrat • OR-6

Sponsored 4/28/2025

Cosponsors (3)

R[
Rep. McCormick, Richard [R-GA-7]

R-GA-7

Joined 4/28/2025

R[
Rep. Riley, Josh [D-NY-19]

D-NY-19

Joined 4/30/2025

Bill Journey

Originated in the House

Introduced

April 28, 2025

Committee Review

April 29, 2025

Ordered to be Reported by Voice Vote.

Floor Debate

July 20, 2026

Passed Chamber

July 20, 2026

Other Chamber

President

Enacted into Law

Text Versions (4)

Referred in Senate7/21/2026
Engrossed in House7/20/2026
Reported in House7/16/2026
Introduced in House4/28/2025

Committee Reports (1)

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors3

Sources and method

· Record updated Nov 17, 2026
  • Congress.govLibrary of Congress
    Status, actions, sponsors, cosponsors, committees and text
    Record updated Nov 17, 2026 · Loaded Nov 17, 2026, 7:59 PM ET
  • CRS bill summaryCongressional Research Service, via Congress.gov
    Official summary
    Summary of the “Introduced in House” version, Apr 28, 2025 · Loaded Nov 17, 2026, 7:59 PM ET
  • CBO cost estimatesCongressional Budget Office
    Cost estimates
    Latest estimate Jun 24, 2025 · Loaded Nov 17, 2026, 7:59 PM ET
  • USAspending.govU.S. Department of the Treasury
    Related Federal Spending section
  • FEC filingsFederal Election Commission
    Funding & Lobbying section
  • Lobbying disclosures (LDA)Secretary of the Senate and Clerk of the House
    Funding & Lobbying section

All sources: Public domain (17 U.S.C. § 105) · Method: Data sources → · Campaign finance →

AI-written text on this page is labeled where it appears. It is written from the sources above and is not a source itself. How we analyze data →

Dates shown where the source reports one. “Loaded” is when CIV.IQ last fetched the record.